The HPA's Biopharmaceutical Production Unit Assists in Vaccine, Therapeutic Protein and Enzyme Product Development
The world class expertise of the Health Protection Agency's Biopharmaceutical Production Unit aids the development of new vaccines, therapeutic proteins and enzyme products, assisting...
Health Protection Agency to Design Laboratories for Samples from Mars
The European Space Agency recently announced that they had appointed the SEA (Group) Ltd to lead a team of experts, including the Health Protection Agency, to define the requirements and...
HPA Receives Capacity Building Award
The Health Protection Agency announced today that it has been awarded a grant that will add to its capacity to deliver wider health benefits to the public and translate its skills and assets...
Further Update on Public Health Issues Related to Polonium-210 Investigation
The Health Protection Agency is continuing to provide expert advice on the public health issues surrounding the death of Mr. Alexander Litvinenko. Throughout, our primary concern has been...
Polonium-210 as a Poison
The Health Protection Agency's radiation protection experts, together with colleagues from research laboratories in the USA, have published a paper in the Journal of Radiological Protection 1...
Update on Public Health Issues Related to Polonium-210 Investigation
The Health Protection Agency is continuing to provide expert advice on the public health issues surrounding the death of Mr. Alexander Litvinenko. Throughout, our primary concern has been...
Meningitis Vaccine Collaboration
Development of a Pan Meningococcal Vaccine for the World The Health Protection Agency (UK) and the Serum Institute of India Ltd have today announced that they have signed a...
Health Protection Agency Commercially Develops Research Programme to Deliver Public Health Benefit
The Health Protection Agency has set up a new company, Syntaxin Ltd, to further realise the health benefits and commercial potential of part of its technology programme, it was announced today. ...
OPi and the UK Health Protection Agency (HPA) Enter into a Worldwide Licensing Agreement on Erwinase®
OPi strengthens its onco-haematology portfolio by being granted exclusive worldwide commercialisation rights for Erwinase® (crisantaspase). OPi SA, Pharmaceuticals for Rare Diseases...